Resumen
Introducción: el síndrome por aglutininas frías (SAF) es una anemia hemolítica mediada por anticuerpos principalmente de tipo IgM, cuya máxima actividad se da a 4 °C. Se presenta en el contexto de enfermedades infecciosas, autoinmunes o neoplásicas por la formación de anticuerpos que tienen reacción cruzada contra antígenos eritrocitarios, particularmente del sistema I. En este trabajo presentamos un caso de SAF asociado a reactivación del virus de Epstein-Barr (VEB) en un paciente con primoinfección por el virus de la inmunodeficiencia humana (VIH).
Caso clínico: hombre de 22 años, sin antecedentes patológicos, hospitalizado por síndrome mononucleósico y anémico. Presentó hemoglobina de 3.7 g/dL y elevación de lactato deshidrogenasa. En el frotis de sangre periférica se observó esferocitosis, policromasia y eritrocitos nucleados. Se confirmó infección por VEB con serología y carga viral, así como infección por VIH seronegativa, con carga viral positiva. La prueba de antiglobulina directa monoespecífica a C3d fue positiva y el rastreo de anticuerpos irregulares demostró un anticuerpo anti-I. El paciente recibió soporte transfusional y tratamiento conservador, con remisión del cuadro a las 2 semanas de su ingreso.
Conclusiones: el SAF es una complicación poco frecuente de la mononucleosis infecciosa, potencialmente mortal, la cual debe ser considerada ante hallazgos sugestivos de hemólisis con la finalidad de iniciar medidas de soporte de forma oportuna.
Abstract
Background: Cold agglutinin syndrome (CAS) is a hemolytic anemia mediated by antibodies, mainly IgM, whose maximum activity occurs at 4 °C. It happens secondary to infectious, autoimmune or neoplastic diseases, due to the formation of antibodies that cross-react against erythrocyte antigens, particularly of the I system. Here, we describe a case of CAS associated to Epstein-Barr virus (EBV) reactivation in a patient with primary human immunodeficiency virus (HIV) infection.
Clinical case: 22-year old man with no medical history, hospitalized due to mononucleosis and anemic syndrome. Hemoglobin of 3.7 g/dL and elevation of lactate dehydrogenase were documented. In the peripheral blood smear it was observed spherocytosis, polychromasia and nucleated erythrocytes. EBV infection was confirmed with serology and viral load, as well as seronegative HIV infection with positive viral load. The C3d monospecific direct antiglobulin test was positive and an irregular antibody screening revealed the presence of an anti-I antibody. The patient received transfusion support and conservative treatment, with remission of the symptoms 2 weeks after admission.
Conclusions: Cold agglutinin syndrome is a rare, potentially fatal complication of infectious mononucleosis, which should be considered in the face of findings suggestive of hemolysis in order to initiate support measures in a timely manner.
Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648. doi: 10.1016/j.blre.2019.100648.
Gertz MA. Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia. Hematol Oncol Clin North Am. 2022;36(2):341-52. doi: 10.1016/j.hoc.2021.11.001.
Barcellini W, Fattizzo B. The Changing Landscape of Autoimmune Hemolytic Anemia. Front Immunol. 2020;11:946. doi: 10.3389/fimmu.2020.00946.
Hill QA, Hill A, Berentsen S. Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment. Blood Adv. 2019;3(12):1897-906. doi: 10.1182/bloodadvances.2019000036.
Thakral B, Bueso-Ramos CE. Unexpected presentation of cold agglutinin syndrome with B-acute lymphoblastic leukemia. Blood. 2022;139(26):3778. doi: 10.1182/blood.2022016015.
Jacobs JW, Gisriel SD. Cold agglutinin syndrome in a patient with anaemia and beta-thalassemia trait. Transfus Med. 2022;32(3):263-4. doi: 10.1111/tme.12864.
Dematapitiya C, Perera C, Chinthaka W, et al. Cold type autoimmune hemolytic anemia- a rare manifestation of infectious mononucleosis; serum ferritin as an important biomarker. BMC Infect Dis. 2019;19(1):68. doi: 10.1186/s12879-019-3722-z.
Teijido J, Tillotson K, Liu JM. A Rare Presentation of Epstein-Barr Virus Infection. J Emerg Med. 2020;58(2):e71-3. doi: 10.1016/j.jemermed.2019.11.043.
Berentsen S. New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia. Front Immunol. 2020;11:590. doi: 10.3389/fimmu.2020.00590.
Klutts JS, Ford BA, Perez NR, et al. Evidence-based approach for interpretation of Epstein-Barr virus serological patterns. J Clin Microbiol. 2009;47(10):3204-10. doi: 10.1128/JCM.00164-09.
Páez-Guillán EM, Campos-Franco J, Alende R, et al. Transient hypertriglyceridemia: a common finding during Epstein-Barr virus-induced infectious mononucleosis. Lipids Health Dis. 2021;20(1):177. doi: 10.1186/s12944-021-01603-9.
Jouini H, Chouaieb S, Boussetta K, et al. Hemophagocytic lymphohistiocytosis associated with an IgG Cold agglutinin. Transfus Clin Biol. 2019;26(4):324-8. doi: 10.1016/j.tracli.2018.08.159.
Berentsen S. Cold agglutinin disease. Hematology Am Soc Hematol Educ Program. 2016(1):226-31. doi: 10.1182/asheducation-2016.1.226.
Berentsen S, Barcellini W. Autoimmune Hemolytic Anemias. N Engl J Med. 2021;385(15):1407-19. doi: 10.1056/NEJMra2033982.
Scheckel CJ, Go RS. Autoimmune Hemolytic Anemia: Diagnosis and Differential Diagnosis. Hematol Oncol Clin North Am. 2022;36(2):315-24. doi: 10.1016/j.hoc.2021.12.001.
Berentsen S. How I treat cold agglutinin disease. Blood. 2021;137(10):1295-303. doi: 10.1182/blood.2019003809.
Berentsen S. How I manage patients with cold agglutinin disease. Br J Haematol. 2018;181(3):320-30. doi: 10.1111/bjh.15109.
Despotovic J, Olmsted T. Cold AIHA and the best treatment strategies. Hematology Am Soc Hematol Educ Program. 2022(1):90-5. doi: 10.1182/hematology.2022000369.
Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood. 2017;129(22):2971-9. doi: 10.1182/blood-2016-11-693689.
Kerr JR. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors. J Clin Pathol. 2019;72(10):651-8. doi: 10.1136/jclinpath-2019-205822.
Röth A, Berentsen S, Barcellini W, et al. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood. 2022;140(9):980-91. doi:10.1182/blood.2021014955.
Gelbenegger G, Jäger U, Fillitz M, et al. Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease. Blood Adv. 2023;7(10):1987-90. doi: 10.1182/bloodadvances.2022008574.
Berentsen S, Barcellini W, D'Sa S, et al. Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?. Immunotherapy. 2022;14(15):1191-204. doi: 10.2217/imt-2022-0085.
Jalink M, Berentsen S, Castillo JJ, et al. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood. 2021;138(20):2002-2005. doi: 10.1182/blood.2021012039.
Rossi G, Gramegna D, Paoloni F, et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood. 2018;132(5):547-550. doi: 10.1182/blood-2018-03-835413.
Tesfaye A, Broome C. A Novel Approach for Treatment of Cold Agglutinin Syndrome-Related Severe Hemolysis. Journal of Hematology. 2016;5(1):30-3.
De Boer ECW, Jalink M, Delvasto-Nuñez L, et al. C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia. Blood Adv. 2023 Jul 11;7(13):3128-3139. doi: 10.1182/bloodadvances.2022009402.
Lodi G, Resca D, Reverberi R. Fatal cold agglutinin-induced haemolytic anaemia: a case report. J Med Case Rep. 2010;4:252. doi: 10.1186/1752-1947-4-252.